TransCode Therapeutics’s (RNAZ) Moving Averages Convergence Divergence (MACD) indicator is -0.09, suggesting TransCode Therapeutics is a Buy.
TransCode Therapeutics’s (RNAZ) 20-Day exponential moving average is $1.66, while TransCode Therapeutics’s (RNAZ) share price is $1.49, making it a Sell.
TransCode Therapeutics’s (RNAZ) 50-Day exponential moving average is $2.12, while TransCode Therapeutics’s (RNAZ) share price is $1.49, making it a Sell.
TransCode Therapeutics’s (RNAZ) 10-Day exponential moving average is $1.60, while TransCode Therapeutics’s (RNAZ) share price is $1.49, making it a Sell.
TransCode Therapeutics’s (RNAZ) 100-Day exponential moving average is $3.28, while TransCode Therapeutics’s (RNAZ) share price is $1.49, making it a Sell.
TransCode Therapeutics’s (RNAZ) stock price is $1.49 and TransCode Therapeutics’s (RNAZ) 50-day simple moving average is $1.74, creating a Sell signal.
TransCode Therapeutics’s (RNAZ) stock price is $1.49 and TransCode Therapeutics’s (RNAZ) 100-day simple moving average is $3.61, creating a Sell signal.
TransCode Therapeutics’s (RNAZ) stock price is $1.49 and TransCode Therapeutics’s (RNAZ) 200-day simple moving average is $5.96, creating a Sell signal.